KODIAK SCIENCES DL-0001
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more
KODIAK SCIENCES DL-0001 (K27) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, KODIAK SCIENCES DL-0001 (K27) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
KODIAK SCIENCES DL-0001 - Net Assets Trend (None–None)
This chart illustrates how KODIAK SCIENCES DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KODIAK SCIENCES DL-0001 (None–None)
The table below shows the annual net assets of KODIAK SCIENCES DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to KODIAK SCIENCES DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
KODIAK SCIENCES DL-0001 Competitors by Market Cap
The table below lists competitors of KODIAK SCIENCES DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Deutsche Pfandbriefbank AG
OTCGREY:PBBGF
|
$681.08 Million |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
$681.15 Million |
|
INMODE LTD IS -01
F:154
|
$681.19 Million |
|
Heineken Bhd
KLSE:3255
|
$681.30 Million |
|
Sigma Lithium Resources Corp
NASDAQ:SGML
|
$680.96 Million |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
$680.61 Million |
|
Carasso Real Estate Ltd
TA:CRSR
|
$680.28 Million |
|
Shandong Gettop Acoustic Co Ltd
SHE:002655
|
$680.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KODIAK SCIENCES DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares KODIAK SCIENCES DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently KODIAK SCIENCES DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares KODIAK SCIENCES DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KODIAK SCIENCES DL-0001 (K27) | €- | N/A | N/A | $681.04 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |